The K-Ras ligand-Linker Conjugate 3 is primarily utilized in the field of targeted cancer therapy, particularly in the development of drugs that specifically inhibit the K-Ras protein, which is often mutated in various cancers. This conjugate plays a crucial role in the design of small molecule inhibitors that can effectively bind to the K-Ras protein, disrupting its signaling pathways and thereby inhibiting tumor growth. In research settings, it is used to study the binding mechanisms and efficacy of potential therapeutic agents. By attaching a linker to the ligand, scientists can enhance the stability and specificity of the drug, ensuring that it reaches its target within the cancerous cells more effectively. This approach is instrumental in advancing personalized medicine, where treatments are tailored to the genetic makeup of an individual's cancer. Furthermore, the conjugate is also employed in the synthesis of PROTACs (Proteolysis Targeting Chimeras), which are bifunctional molecules designed to degrade specific proteins. In this context, the K-Ras ligand-Linker Conjugate 3 helps in the targeted degradation of the K-Ras protein, offering a novel therapeutic strategy for cancers that are driven by K-Ras mutations. This application holds promise for overcoming drug resistance and improving outcomes in patients with K-Ras-driven malignancies.